Literature DB >> 11333147

DNA methylation and carcinogenesis.

A V Lichtenstein1, N P Kisseljova.   

Abstract

In the world of easy things truth is opposed to lie; in the world of complicated things one profound truth is opposed to another not less profound than the first. Neils Bohr The hypothesis of the exclusively genetic origin of cancer ("cancer is a disease of genes, a tumor without any damage to the genome does not exist") dominated in the oncology until recently. A considerable amount of data confirming this hypothesis was accumulated during the last quarter of the last century. It was demonstrated that the accumulation of damage of specific genes lies at the origin of a tumor and its following progression. The damage gives rise to structural changes in the respective proteins and, consequently, to inappropriate mitogenic stimulation of cells (activation of oncogenes) or to the inactivation of tumor suppressor genes that inhibit cell division, or to the combination of both (in most cases). According to an alternative (epigenetic) hypothesis that was extremely unpopular until recently, a tumor is caused not by a gene damage, but by an inappropriate function of genes ("cancer is a disease of gene regulation and differentiation"). However, recent studies led to the convergence of these hypotheses that initially seemed to be contradictory. It was established that both factors--genetic and epigenetic--lie at the origin of carcinogenesis. The relative contribution of each varies significantly in different human tumors. Suppressor genes and genes of repair are inactivated in tumors due to their damage or methylation of their promoters (in the latter case an "epimutation", an epigenetic equivalent of a mutation, occurs, producing the same functional consequences). It is becoming evident that not only the mutagens, but various factors influencing cell metabolism, notably methylation, should be considered as carcinogens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333147     DOI: 10.1023/a:1010249510906

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  6 in total

1.  Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer.

Authors:  Shahana Majid; Altaf A Dar; Varahram Shahryari; Hiroshi Hirata; Ardalan Ahmad; Sharanjot Saini; Yuichiro Tanaka; Angela V Dahiya; Rajvir Dahiya
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

Review 2.  Methylation in esophageal carcinogenesis.

Authors:  Da-Long Wu; Feng-Ying Sui; Xiao-Ming Jiang; Xiao-Hong Jiang
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

3.  Effects on specific promoter DNA methylation in zebrafish embryos and larvae following benzo[a]pyrene exposure.

Authors:  J Corrales; X Fang; C Thornton; W Mei; W B Barbazuk; M Duke; B E Scheffler; K L Willett
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2014-02-24       Impact factor: 3.228

Review 4.  Molecular mechanisms of chemopreventive phytochemicals against gastroenterological cancer development.

Authors:  Min-Yu Chung; Tae Gyu Lim; Ki Won Lee
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

5.  Association of GEMIN4 gene polymorphism and the risk of cancer: a meta-analysis.

Authors:  Nan Wu; Xiaowei Zhang; Jinlong Tian; Shuang Yu; Ying Qiao
Journal:  Onco Targets Ther       Date:  2017-11-02       Impact factor: 4.147

6.  Proteasome activator PA200 maintains stability of histone marks during transcription and aging.

Authors:  Tian-Xia Jiang; Shuang Ma; Xia Han; Zi-Yu Luo; Qian-Qian Zhu; Tomoki Chiba; Wei Xie; Kui Lin; Xiao-Bo Qiu
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.